In this week's Pharma Pulse, Cencora agrees to acquire American Oncology Network, five major employers back electronic prior authorization for self-funded health plans and FDA finalizes its guidance on prescription drug apps and software.
Commentary|Podcasts|January 9, 2026
Pharma Pulse: Merger Fever, Lilly’s $1.2B Inflammatory Bet, and the Birth of CareTria
Author(s)Nicholas Saraceno, Senior Editor
In today’s Pharma Pulse, healthcare leaders brace for a surge in dealmaking, Eli Lilly secures a suite of oral NLRP3 inhibitors, and Knipper Health rebrands to streamline the path from order to therapy.
Advertisement
Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and let’s get into today’s headlines.
- We begin with a pulse check on industry dealmaking. According to a
new KPMG survey , 2026 is shaping up to be a year of significant consolidation. Nearly three-quarters of life sciences executives and 61% of healthcare leaders expect merger activity to ramp up this year. While healthcare systems face uncertainty over federal policies and reimbursement, the overall sentiment is bullish, with leaders looking to mergers as a primary lever for growth and operational scale after a period of relative caution. - In one of the year’s first major biopharma blockbuster deals, Eli Lilly has entered a definitive $1.2 billion agreement to acquire Ventyx Biosciences. This
all-cash transaction brings Ventyx’s promising pipeline of oral small-molecule NLRP3 inhibitors into the Lilly portfolio. These candidates target residual and chronic inflammation, which is increasingly recognized as a hidden driver in cardiometabolic health, neurodegeneration, and autoimmune diseases. - Lastly, a major evolution in the pharma services sector. Knipper Health has officially rebranded as
CareTria . The shift marks the company’s transition into a fully integrated therapy initiation platform. Following the acquisition of eBlu Solutions, Caretria is integrating digital enrollment, real-time benefit investigation, and multi-modal fulfillment into a single ecosystem.
That’s it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access and care delivery, visit
Thanks for listening—until next time, stay well and stay informed.
You can catch Pharma Pulse directly on
Advertisement
Related to this article
In this week's Pharma Pulse, DHL adds six dedicated cold chain air corridors linking Europe and North America to Asia, Walmart rolls out a $0 prescription tier and rare disease Center of Excellence for its US workforce and FDA launches its Rare Disease Framework Initiative.
In this week's Pharma Pulse, PhRMA sues to block CMS's GLOBE pricing model, WFS opens a temperature-controlled cargo terminal in Lyon and Bayer commits $2.2 billion to a new Ohio manufacturing site.
Walgreens adds GLP-1 coverage navigation, Medicare Bridge support and pharmacist outreach to its virtual weight management service.
GEODIS' David Frouin explains why securing the lane outranks sustainability and why full corridor models are the cold chain trend to watch.
BMS’s Kevin Cook explains why digital capability is becoming a must-have for strategic CMO partners and why the next phase starts with the basics.
Agentic AI is moving biopharma from tools that inform decisions to systems that execute them, reshaping discovery, clinical trials, commercial launch and regulatory work.
At LogiPharma USA 2026, Freehand's Nitin Jayakrishnan explains why AI and the people supply chain will shape pharma supply strategy.
Advertisement
Advertisement